Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 2041-2045

  Holdenrieder, Stefan ^a   Eichhorn, Peter ^a   Beuers, Ulrich ^a   Samtleben, Walter ^a   Stieber, Petra ^a   Nagel, Dorothea ^a   Peterfi, Andrea ^b   Steinle, Alexander ^c   Salih, Helmut Rainer ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Autoimmune diseases; Cancer; Cholestasis; Diagnosis; Infection; MICA; MICB; NKG2D; Renal insufficiency; Serum

Indexed keywords

GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN B; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; CHOLESTASIS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIGANDS; LIVER DISEASES; RECEPTORS, IMMUNOLOGIC;

EID: 34250770417     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Bahram S: MIC genes: from genetics to biology. Adv Immunol 76: 1-60, 2000.
2. Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727, 2006.
3. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790, 2003.
4. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL and Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729, 1999.
5. Cerwenka A, Baron JL and Lanier LL: Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98: 11521-11526, 2001.
6. Gonzales S, Groh V and Spies T: Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298: 121-138, 2006.
7. Salih HR, Rammensee HG and Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-5002, 2002.
8. Lanier LL: NK cell recognition. Annu Rev Immunol 23: 225-274, 2005.
9. Groh V, Wu J, Yee C and Spies T: Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738, 2002.
10. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG and Steinle A: Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396, 2003.
11. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICA in malignant diseases. Int J Cancer 118: 684-687, 2006.
12. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 55: 1584-1589, 2006.
13. Salih HR, Goehlsdorf D and Steinle A: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67: 188-195, 2006.
14. Stieber P: Sensible use of tumor markers. J Lab Med 25: 327-336, 2001.